Renal cell carcinoma (RCC) is the most common primary renal neoplasm. Here we present a patient with a 3 month onset of lower extremity swelling and worsening renal function found to be due to advanced RCC with extensive tumor burden and rapid subsequent decline.
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A middle-aged patient was referred to nephrology clinic for proteinuria and an elevated creatinine from a baseline of 0.9 to 1.5mg/dL over three months. The patient complained of bilateral leg swelling, shortness of breath, weakness, five-pound weight loss over the last 3 months. Vital signs were unremarkable. Physical examination was notable for 2+ bilateral ankle edema. CMP was unremarkable except for a creatinine of 1.5mg/dL and alkaline phosphatase of 581U/L (100U/L three months ago). Urine protein/creatinine ratio was 4.29. Blood electrophoresis with immunofixation and free light chain ratio were all within normal range. The patient had normocytic anemia (Hgb 9.8mg/dL), iron saturation of 10%. Renal ultrasound revealed a thickened left renal cortex and poorly visualized left renal vein. Subsequent imaging revealed a 6cm left renal mass with tumor thrombus in the left renal vein with extension into the IVC from the iliac vein bifurcation to the right atrium. A lytic lesion was noted in the L2 spine. A biopsy of the lytic lesion revealed metastatic clear cell RCC. The patient rapidly deteriorated from obstructive shock, acute renal failure, significant acidosis, congestive hepatopathy, and transudative ascites (with no tumor cells).
RCC should always be a part of the differential diagnosis when evaluating leg swelling, proteinuria, or elevated creatinine.  https://doi.org/10.32873/unmc.dc.gmerj.1.1.071
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Introduction: C3 glomerulonephritis (C3GN) is a glomerular disease caused by excessive activation of the alternative complement pathway and often leads to end-stage renal disease. Following kidney transplantation, the recurrence risk is high and may cause premature allograft failure. Eculizumab prevents the membrane attack complex (MAC) formation and provides terminal complement inhibition. Here we present a case of early recurrent post-transplant C3GN in a patient with a C3 gene mutation that was successfully treated with eculizumab.
Case Description:
A middle-aged patient with a history of chronic kidney disease received a living unrelated kidney transplant. Prior to the transplant, the patient was diagnosed with C3GN which was refractory to corticosteroids, mycophenolate, and rituximab. Evaluation revealed a C3 gain of function mutation. Complement inhibitory factors were normal and the patient did not have a C3 nephritic factor. An elevated level of soluble MAC (sMAC) was noted prior to transplantation. The patient had immediate graft function following transplant and was maintained on tacrolimus, mycophenolate, and prednisone following basiliximab induction. The patient's creatinine reached a nadir of 1.1 mg/dl, but he/she developed early acute allograft dysfunction and proteinuria within the first few weeks of transplant and biopsy revealed early recurrence of C3GN. The patient was treated with high dose corticosteroids and plasmapheresis, but continued progression of renal dysfunction with rising sMAC levels, proteinuria, and activity of C3GN on a repeat biopsy. After initiation of eculizumab, the sMAC levels normalized, proteinuria resolved, and the allograft function improved. The patient is now >1 year out from transplantation with stable allograft function and no evidence of complications related to the eculizumab.
Discussion: Eculizumab appears to have a role in select patients with recurrent C3GN. Since not all patients with C3GN improve with eculizumab, more research is needed to define patients expected to benefit from this therapy. Patients with recurrent C3GN due to a gain of function mutation in the C3 gene should be considered for early eculizumab therapy to preserve allograft function and decrease excessive complement activity.  https://doi.org/10.32873/unmc.dc.gmerj.1.1.072 glioma. Patients with unknown surgery, RT, or chemotherapy status were excluded, along with patients <40 years old who underwent gross total resection to coincide with RTOG 9802 exclusion criteria. Chi squared, Fisher's exact or Wilcoxon rank-sum tests evaluated differences in characteristics between groups. Kaplan-Meier analysis was used to evaluate overall survival (OS) between groups (sCRT vs. cCRT). Cox proportional hazards modeling determined variables associated with OS. Conclusions: This is the only known analysis of cCRT versus sCRT for LGG. There is no evidence that cCRT improves outcomes over sCRT.  https://doi.org/10.32873/unmc.dc.gmerj.1.1.073
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